The conversation discusses the potential effects of spearmint on acne and male pattern baldness (MPB). Concerns are raised about spearmint's androgen-suppressing effects and its suitability for men.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
Vitamin D3 deficiency and gut health, particularly H. pylori overgrowth, can impact hair growth and overall health. Treatments like Minoxidil and finasteride may be ineffective if these issues are not addressed.
The conversation is about adjusting the dosage of topical Finasteride to avoid side effects like chest pain and breast swelling. The user is considering reducing the concentration to 0.1% or trying microdosing with 0.01-0.025% for lower systemic effects.
A user experienced worsened hair condition after a PRP session and is considering stopping further sessions. They are using a Dermapen, electric massage, iron, saw palmetto, and plan to start minoxidil, but have had side effects with finasteride and are advised to consider dutasteride under medical supervision.
The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.
A 31-year-old man using finasteride for a year is considering adding oral minoxidil or switching to topical minoxidil to address diffuse thinning, while also using a scalp massager and ketoconazole shampoo. Concerns include cardiovascular side effects, pet safety with topical minoxidil, and cost of telehealth services.
The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.
Phase 3 for PP405 will start in 2027, disappointing many who expected it this year. Some users are trying treatments like topical minoxidil and topical dutasteride while waiting for new developments.
Concerns about dermarolling potentially causing collagen breakdown and cancer, with skepticism about the claims due to lack of scientific evidence. Users express doubts and discuss the validity of the article's claims.
A dermatologist refused to prescribe finasteride due to concerns about recent research linking it to male breast cancer, suggesting a topical alternative with minoxidil instead. The user is advised to seek a second opinion, as the evidence for such risks is inconclusive and the dermatologist's reasoning seems questionable.
A 25-year-old male experiencing diffuse thinning is advised to address high TSH levels and low iron, and consider treatments like finasteride. Weight loss and improved diet are also suggested to potentially help with hair health.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
The conversation discusses the use of 0.1% latanoprost for hair regrowth, with concerns about cost and dependency. The user currently uses dutasteride and oral minoxidil and is considering adding latanoprost to their regimen.
Pattern hair loss before age 35 may be linked to higher risks of prostate cancer, cardiovascular diseases, and metabolic syndrome later in life. Finasteride is discussed as a treatment that may lower PSA levels and potentially prevent prostate issues.
A user shared his experience of having two healthy children while continuously using finasteride (Fin) for hair loss, challenging fears about its potential impact on fetal development. The discussion that followed included various perspectives, with some users sharing similar experiences, others expressing concerns about potential risks, and some emphasizing the need for more substantial evidence before drawing conclusions.
The conversation discusses hair loss caused by Trenbolone use, with suggestions to stop using it and consider treatments like Minoxidil, Dutasteride, and RU58841. It highlights that Minoxidil may temporarily regrow hair, but stopping Trenbolone is crucial to prevent further hair loss.
People with diffuse thinning and retrograde hair loss are discussing treatments like finasteride, minoxidil, and dutasteride, with some reporting improvements and others experiencing issues like scalp inflammation and increased sebum. Suggestions include addressing scalp inflammation, considering gut health, and possibly using topical antiandrogens or micro-needling.
Oral minoxidil may cause facial bloating and dark circles, making some users feel they look older. Some consider reducing the dosage or switching treatments due to these side effects.
Minoxidil can cause facial bloat, which some users manage by adjusting sodium intake or using it only on the scalp. Alternatives like finasteride or dutasteride are suggested for those concerned about facial changes.
Bald people have a higher risk of skin cancer, especially on the scalp, and wearing a hat is suggested as a solution. Hair loss treatments like Minoxidil, finasteride, and RU58841 are not mentioned in this conversation.
Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.
PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
The conversation discusses hair loss treatments for a woman experiencing androgenetic alopecia and seborrheic dermatitis, with suggestions including low-dose oral minoxidil, dutasteride, and hormone replacement therapy. The user is seeking advice due to intolerance to spironolactone and topical minoxidil, and concerns about low testosterone and DHT levels.
Managing blood pressure can help with hair loss, as seen with the use of medications like Cialis and oral minoxidil, which improved hairline and blood pressure. Lifestyle changes, such as reducing stimulant use and adjusting testosterone replacement therapy (TRT) doses, also play a role in addressing hair loss and overall health.
The user is experiencing worsening hair loss despite using finasteride and is advised to add minoxidil to their treatment. Concerns about side effects and the effectiveness of combining finasteride and minoxidil are discussed.
Finasteride can cause sexual side effects, and reducing porn and masturbation may help improve sexual function. Some users experience persistent issues even after stopping finasteride.
The user is frustrated with minoxidil's lack of results and is considering alternatives like oral minoxidil or finasteride despite concerns about side effects. Other suggestions include consulting a doctor, adjusting dosages, or considering a hair transplant.
The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.